Literature DB >> 33583072

Leucine Zipper 4 Autoantibody: A Novel Germ Cell Tumor and Paraneoplastic Biomarker.

Divyanshu Dubey1,2,3, Thomas Kryzer2,3, Yong Guo1,3, Benjamin Clarkson1,3, John C Cheville2, Brian A Costello4, Bradley C Leibovich5, Alicia Algeciras-Schimnich2, Claudia Lucchinnetti1,3, M Bakri Hammami2, Andrew M Knight2, Charles Howe1,3, Vanda A Lennon1,2,3,6, Andrew McKeon1,2,3, Sean J Pittock1,2,3.   

Abstract

OBJECTIVE: This study was undertaken to describe a novel biomarker of germ cell tumor and associated paraneoplastic neurological syndrome (PNS).
METHODS: Archival sera from patients with germ cell tumor-associated PNS were evaluated. We identified a common autoantigen in a human testicular cancer cell line (TCam-2) by Western blot and mass spectrometry. Its identity was confirmed by recombinant-protein Western blot, enzyme-linked immunosorbent assay (ELISA), and cell-based assay. Autoantibody specificity was confirmed by analyzing assorted control sera/cerebrospinal fluid.
RESULTS: Leucine zipper 4 (LUZP4)-immunoglobulin G (IgG) was detected in 28 patients' sera, 26 of whom (93%) were men. The median age at neurological symptom onset was 45 years (range = 28-84). Median titer (ELISA) was 1:300 (1:50 to >1:6,400, normal value < 1:50). Coexistent kelchlike protein 11-IgG was identified in 18 cases (64%). The most common presenting phenotype was rhombencephalitis (17/28, 61%). Other presentations included limbic encephalitis (n = 5, 18%), seizures and/or encephalitis (n = 2, 7%), and motor neuronopathy/polyradiculopathy (n = 4, 14%). The most common malignancy among cancer-evaluated PNS patients was seminoma (21/27, 78%). Nine of the 21 seminomas detected by whole-body fluorodeoxyglucose positron emission tomography scan (43%) were extratesticular. Both female patients had ovarian teratoma. Regressed testicular germ cell tumors were found in 4 patients. Exposure of T-cell-dendritic-cell cocultures from chronic immunosuppression-naïve LUZP4-IgG-seropositive patients to recombinant LUZP4 protein evoked a marked increase in CD69 expression on both CD4+ and CD8+ T cells when compared to vehicle-exposed and healthy control cultures.
INTERPRETATION: LUZP4-IgG represents a novel serological biomarker of PNS and has high predictive value for germ cell tumors. The demonstrated antigen-specific T-cell responses support a CD8+ T-cell-mediated cytotoxic paraneoplastic and antitumor potential. ANN NEUROL 2021;89:1001-1010.
© 2021 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33583072     DOI: 10.1002/ana.26050

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  5 in total

Review 1.  Paraneoplastic neurological syndrome: growing spectrum and relevance.

Authors:  Valakunja Harikrishna Ganaraja; Mohamed Rezk; Divyanshu Dubey
Journal:  Neurol Sci       Date:  2022-04-23       Impact factor: 3.307

Review 2.  Novelties in Autoimmune and Paraneoplastic Cerebellar Ataxias: Twenty Years of Progresses.

Authors:  Sergio Muñiz-Castrillo; Alberto Vogrig; Nicolás Lundahl Ciano-Petersen; Macarena Villagrán-García; Bastien Joubert; Jérôme Honnorat
Journal:  Cerebellum       Date:  2022-01-12       Impact factor: 3.648

Review 3.  Paraneoplastic Neurological Syndromes: Transitioning Between the Old and the New.

Authors:  Diego Franciotta; Lorenzo Lorusso; Matteo Gastaldi; Silvia Scaranzin; Businaro Pietro; Anastasia Lechiara; Giampaola Pesce
Journal:  Curr Oncol Rep       Date:  2022-04-27       Impact factor: 5.945

Review 4.  Ovarian Teratoma-Related Paraneoplastic Neurological Syndromes.

Authors:  Jingfang Lin; Minjin Wang; Jierui Wang; Jinmei Li
Journal:  Front Oncol       Date:  2022-05-16       Impact factor: 5.738

5.  Population-Based Epidemiology Study of Paraneoplastic Neurologic Syndromes.

Authors:  Shailee Shah; Eoin P Flanagan; Pritikanta Paul; Carin Y Smith; Sandra C Bryant; Michelle F Devine; Vanda A Lennon; Andrew McKeon; Sean J Pittock; Divyanshu Dubey
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-12-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.